MCID: PDT021
MIFTS: 40

Pediatric Osteosarcoma

Categories: Cancer diseases, Bone diseases

Aliases & Classifications for Pediatric Osteosarcoma

MalaCards integrated aliases for Pediatric Osteosarcoma:

Name: Pediatric Osteosarcoma 12 15
Childhood Osteosarcoma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:3361
NCIt 50 C6585
UMLS 73 C1332986

Summaries for Pediatric Osteosarcoma

MalaCards based summary : Pediatric Osteosarcoma, also known as childhood osteosarcoma, is related to methotrexate toxicity or dose selection and acute lymphoblastic leukemia, childhood. An important gene associated with Pediatric Osteosarcoma is SLC19A1 (Solute Carrier Family 19 Member 1), and among its related pathways/superpathways are Metabolism of water-soluble vitamins and cofactors and Folate Metabolism. The drugs Dalteparin and Heparin have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and lung, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Pediatric Osteosarcoma

Diseases related to Pediatric Osteosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 12)
# Related Disease Score Top Affiliating Genes
1 methotrexate toxicity or dose selection 10.3 MTHFR SLC19A1
2 acute lymphoblastic leukemia, childhood 10.2 MTHFR SLC19A1
3 transcobalamin ii deficiency 10.2 DHFR MTHFR
4 myelomeningocele 10.2 MTHFR SLC19A1
5 homocysteinemia 10.1 MTHFR SLC19A1
6 sarcoma 9.8
7 megaloblastic anemia 9.8 DHFR MTHFR
8 neural tube defects 9.7 DHFR MTHFR SLC19A1
9 acute lymphocytic leukemia 9.6 MTHFR SLC19A1
10 ewing sarcoma 9.6
11 osteochondroma 9.6
12 hutchinson-gilford progeria syndrome 9.6 RFC1 ROCK1

Graphical network of the top 20 diseases related to Pediatric Osteosarcoma:



Diseases related to Pediatric Osteosarcoma

Symptoms & Phenotypes for Pediatric Osteosarcoma

GenomeRNAi Phenotypes related to Pediatric Osteosarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.44 MTHFR
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.44 MTHFR
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.44 MTHFR
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 9.44 DHFR
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 9.44 MTHFR
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.44 MTHFR
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.44 MTHFR
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-86 9.44 DHFR FAS MTHFR
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.44 DHFR MTHFR
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.44 MTHFR

MGI Mouse Phenotypes related to Pediatric Osteosarcoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.7 DHFR FAS HK2 MTHFR RFC1 ROCK1
2 integument MP:0010771 9.35 DHFR FAS MTHFR ROCK1 SLC19A1
3 mortality/aging MP:0010768 9.17 DHFR FAS HK2 MTHFR RFC1 ROCK1

Drugs & Therapeutics for Pediatric Osteosarcoma

Drugs for Pediatric Osteosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 319)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dalteparin Approved Phase 4,Not Applicable 9005-49-6
2
Heparin Approved, Investigational Phase 4,Not Applicable 9005-49-6 772 46507594
3
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
4
Enoxaparin Approved Phase 4 9005-49-6 772
5 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
7 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
8 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
9 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Central Nervous System Depressants Phase 4,Phase 3,Phase 1
12 Cyclooxygenase Inhibitors Phase 4,Phase 2,Not Applicable
13 Antidepressive Agents Phase 4
14 Antimanic Agents Phase 4,Phase 1
15 Lithium carbonate Phase 4 554-13-2
16 Psychotropic Drugs Phase 4,Phase 1
17 Tranquilizing Agents Phase 4,Phase 1
18 Anticoagulants Phase 4,Not Applicable
19 calcium heparin Phase 4,Not Applicable
20 Fibrinolytic Agents Phase 4,Not Applicable
21 Heparin, Low-Molecular-Weight Phase 4,Not Applicable
22 Antipyretics Phase 4
23 Platelet Aggregation Inhibitors Phase 4
24
Cisplatin Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
25
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 23214-92-8 31703
26
Ifosfamide Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 3778-73-2 3690
27
Zoledronic acid Approved Phase 2, Phase 3,Phase 3,Phase 1 118072-93-8 68740
28
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 50-02-2 5743
29
Diphenhydramine Approved, Investigational Phase 2, Phase 3 147-24-0, 58-73-1 3100
30
Docetaxel Approved, Investigational Phase 2, Phase 3,Phase 1 114977-28-5 148124
31
Gemcitabine Approved Phase 2, Phase 3,Phase 1,Not Applicable 95058-81-4 60750
32
Promethazine Approved, Investigational Phase 2, Phase 3 60-87-7 4927
33
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
34
Dactinomycin Approved, Investigational Phase 3,Phase 2,Not Applicable 50-76-0 2019 457193
35
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
36
Mesna Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 3375-50-6 598
37
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
38
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
39
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
40
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable 148-82-3 4053 460612
41
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
42
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
43
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
44
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
45
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
46
Sorafenib Approved, Investigational Phase 2, Phase 3,Phase 1 284461-73-0 216239 406563
47
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
48
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
49 Mifamurtide Approved, Experimental Phase 2, Phase 3 838853-48-8
50
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 119413-54-6, 123948-87-8 60700

Interventional clinical trials:

(show top 50) (show all 427)
# Name Status NCT ID Phase Drugs
1 Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma Recruiting NCT01669369 Phase 4 Lithium Carbonate;Placebo
2 Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology Enrolling by invitation NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
3 Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma Unknown status NCT00691236 Phase 2, Phase 3 Zoledronic acid;Standard chemotherapy
4 A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma Unknown status NCT02099396 Phase 2, Phase 3 Docetaxel+lobaplatin;Gemcitabine+lobaplatin
5 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
6 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
7 Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy Completed NCT02711007 Phase 2, Phase 3 apatinib
8 Comparison of High-Dose Methotrexate (HDM) Plus Doxorubicin to HDM Plus Etoposide-Ifosfamide in Osteosarcoma Children Completed NCT00180908 Phase 3 Etoposide, Ifosfamide, Methotrexate;Doxorubicin, Methotrexate
9 Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma Completed NCT01176981 Phase 3 High Dose Methotrexate
10 Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study Completed NCT00001217 Phase 3 pre-surgical chemotherapy
11 Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma Completed NCT00002539 Phase 3 cisplatin;doxorubicin hydrochloride
12 Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma Completed NCT00003937 Phase 3 cisplatin;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;methotrexate
13 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3 sodium thiosulfate
14 Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) Completed NCT00538239 Phase 3 ridaforolimus;Placebo
15 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
16 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
17 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
18 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
19 Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor Completed NCT00006734 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
20 ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma Recruiting NCT01459484 Phase 2, Phase 3 Mifamurtide arm
21 Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer Recruiting NCT01916317 Phase 3 0.5% lignocaine 60mM
22 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
23 Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma Recruiting NCT01091883 Phase 3
24 Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma Recruiting NCT02063022 Phase 3 Standard treatment (as per protocol ISG SSG III);Intensified chemotherapy
25 Study in Localized and Disseminated Ewing Sarcoma Recruiting NCT00987636 Phase 3 Zoledronic acid;Busulfan;Treosulfan
26 Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma Recruiting NCT02306161 Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Vincristine Sulfate
27 Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma Active, not recruiting NCT00134030 Phase 3 Cisplatin;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Methotrexate
28 Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer Active, not recruiting NCT02856048 Phase 2, Phase 3 Triptorelin (GnRHa) + Chemotherapy
29 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Active, not recruiting NCT01987596 Phase 3
30 Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Active, not recruiting NCT01231906 Phase 3 vincristine sulfate;doxorubicin hydrochloride;cyclophosphamide;ifosfamide;etoposide;topotecan hydrochloride
31 Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma Not yet recruiting NCT03495921 Phase 3 Irinotecan;Temozolomide
32 Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma Terminated NCT00470223 Phase 3 cisplatin;doxorubicin hydrochloride;etoposide;ifosfamide;methotrexate;zoledronic acid
33 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
34 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
35 Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia Terminated NCT00127387 Phase 2, Phase 3 Enbrel
36 Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients Withdrawn NCT01734863 Phase 3
37 Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma Withdrawn NCT00334867 Phase 3 cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate
38 Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma Unknown status NCT01216826 Phase 2 Everolimus
39 A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma Unknown status NCT01002092 Phase 2 Chemotherapy;Endostar
40 Pilot Study of Curcumin Formulation and Ashwagandha Extract in Advanced Osteosarcoma Unknown status NCT00689195 Phase 1, Phase 2
41 Prospective Clinical Trial Evaluating Metronomic Chemotherapy in Patients With High-grade, Operable, Non-metastatic Osteosarcoma of the Extremity Unknown status NCT02273583 Phase 2 continuous oral cyclophosphamide and methotrexate
42 Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse Unknown status NCT00180947 Phase 2 Vinorelbine, cyclofosfamide
43 The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous Cytokine-induced Killer Cells Unknown status NCT01868490 Phase 1, Phase 2 cytokine induced killer cells
44 Interferon Alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma Unknown status NCT00026416 Phase 2 thalidomide
45 Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults Unknown status NCT01696669 Phase 2 Chemotherapy
46 Hematopoietic Stem Cell Transplantation From Human Leukocyte Antigen (HLA) Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas Unknown status NCT00998361 Phase 2
47 Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Unknown status NCT00179816 Phase 1, Phase 2 High-Dose Chemotherapy with Tandem PBSC Rescue.
48 Trial With Gemcitabine and Rapamycin in Second Line of Metastatic Osteosarcoma Completed NCT02429973 Phase 2 Gemcitabine plus rapamycin
49 A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS) Completed NCT02441309 Phase 2 Mifamurtide;Ifosfamide
50 Recombinant Interferon Alpha and Etoposide in Relapsed Osteosarcoma Completed NCT00504140 Phase 2 Etoposide;Interferon Alpha

Search NIH Clinical Center for Pediatric Osteosarcoma

Genetic Tests for Pediatric Osteosarcoma

Anatomical Context for Pediatric Osteosarcoma

MalaCards organs/tissues related to Pediatric Osteosarcoma:

41
Bone, T Cells, Lung, Testes, Brain, Nk Cells, Bone Marrow

Publications for Pediatric Osteosarcoma

Articles related to Pediatric Osteosarcoma:

(show top 50) (show all 84)
# Title Authors Year
1
miRa89188 suppresses tumor progression by targeting SOX4 in pediatric osteosarcoma. ( 29749512 )
2018
2
Prognostic Value of Metabolic and Volumetric Parameters of FDG PET in Pediatric Osteosarcoma: A Hypothesis-generating Study. ( 29357275 )
2018
3
Biological function of microRNA-30c/SOX9 in pediatric osteosarcoma cell growth and metastasis. ( 29364496 )
2018
4
Carbon ion radiotherapy for inoperable pediatric osteosarcoma. ( 29796166 )
2018
5
The Effect of Clown Intervention on Self-Report and Biomarker Measures of Stress and Fatigue in Pediatric Osteosarcoma Inpatients: A Pilot Study. ( 29900751 )
2018
6
TRIM37 promotes tumor cell proliferation and drug resistance in pediatric osteosarcoma. ( 29163677 )
2017
7
Ambulatory High-dose Methotrexate Administration in Pediatric Osteosarcoma Patients at a Single Institution in Argentina. ( 28937522 )
2017
8
Pediatric Osteosarcoma: An Updated Review. ( 28469335 )
2017
9
Quantitative diffusion-weighted magnetic resonance imaging assessment of chemotherapy treatment response of pediatric osteosarcoma and Ewing sarcoma malignant bone tumors. ( 28806574 )
2017
10
The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients. ( 28592186 )
2017
11
Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: A case report. ( 29390436 )
2017
12
The expression and function of miRNA-106 in pediatric osteosarcoma. ( 28272712 )
2017
13
Immunotherapeutic approaches in pediatric osteosarcoma. ( 28353326 )
2017
14
ATIC Gene Polymorphism and Histologic Response to Chemotherapy in Pediatric Osteosarcoma. ( 28267080 )
2017
15
Pharmacological or genetic inhibition of LDHA reverses tumor progression of pediatric osteosarcoma. ( 27261617 )
2016
16
CUL4A expression in pediatric osteosarcoma tissues and its effect on cell growth in osteosarcoma cells. ( 26715273 )
2016
17
Multimodality Imaging in Pediatric Osteosarcoma in the Era of Image Gently and Image Wisely Campaign With a Close Look at the CT Scan Radiation Dose. ( 26583624 )
2016
18
Novel insights and therapeutic interventions for pediatric osteosarcoma. ( 27651036 )
2016
19
Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma. ( 27104192 )
2016
20
The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma. ( 26603261 )
2016
21
Efficacy of pamidronate in pediatric osteosarcoma patients with low bone mineral density. ( 27104175 )
2016
22
Bone mineral density change during adjuvant chemotherapy in pediatric osteosarcoma. ( 26512351 )
2015
23
PI3K/Akt signaling mediated Hexokinase-2 expression inhibits cell apoptosis and promotes tumor growth in pediatric osteosarcoma. ( 26116768 )
2015
24
Experience of Pediatric Osteosarcoma of the Extremity at a Single Institution in Taiwan: Prognostic Factors and Impact on Survival. ( 25323470 )
2014
25
Upregulated expression of microRNA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma. ( 24038809 )
2014
26
Impaired testicular function after an ifosfamide-containing regimen for pediatric osteosarcoma: a case series and review of the literature. ( 24667129 )
2014
27
In silico functional analyses and discovery of survival-associated microRNA signatures in pediatric osteosarcoma. ( 25594070 )
2014
28
Management of local recurrence of pediatric osteosarcoma following limb-sparing surgery. ( 24558066 )
2014
29
Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience. ( 25520112 )
2014
30
Pediatric Osteosarcoma: A Single Institution's Experience. ( 25365431 )
2014
31
Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. ( 24703847 )
2014
32
Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand. ( 23621194 )
2013
33
Bronchioloalveolar carcinoma as a second malignancy in a pediatric osteosarcoma survivor: case report. ( 23758793 )
2013
34
Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma. ( 23430441 )
2013
35
Endothelin-1 gene polymorphisms and risk of chemoresistant pediatric osteosarcoma. ( 24123836 )
2013
36
Combined MicroRNA-340 and ROCK1 mRNA Profiling Predicts Tumor Progression and Prognosis in Pediatric Osteosarcoma. ( 24398981 )
2013
37
Pathological fracture as the presenting feature in pediatric osteosarcoma. ( 23281226 )
2013
38
Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma. ( 22652833 )
2012
39
Correlation of non-mass-like abnormal MR signal intensity with pathological findings surrounding pediatric osteosarcoma and Ewing's sarcoma. ( 22406919 )
2012
40
Plasma proteomic profiling of pediatric osteosarcoma. ( 22083817 )
2012
41
Serum tumor markers in pediatric osteosarcoma: a summary review. ( 22587902 )
2012
42
Case-parent analysis of variation in pubertal hormone genes and pediatric osteosarcoma: a Children's Oncology Group (COG) study. ( 23205180 )
2012
43
Location of pulmonary metastasis in pediatric osteosarcoma is predictive of outcome. ( 21763830 )
2011
44
Elevated expression of CXC chemokines in pediatric osteosarcoma patients. ( 20806347 )
2011
45
Two pediatric osteosarcoma cases with delayed methotrexate excretion: its clinical course and management. ( 21509165 )
2011
46
Survival outcomes of pediatric osteosarcoma and Ewing's sarcoma: a comparison of surgery type within the SEER database, 1988-2007. ( 22223058 )
2011
47
Primary pediatric osteosarcoma of the skull. ( 22134292 )
2011
48
Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma. ( 20734401 )
2010
49
Ambulatory high-dose methotrexate administration among pediatric osteosarcoma patients in an urban, underserved setting is feasible, safe, and cost-effective. ( 20949591 )
2010
50
Lengthening of intercalary allograft combined with free vascularized fibular graft after reconstruction in pediatric osteosarcoma of femur. ( 19950438 )
2010

Variations for Pediatric Osteosarcoma

Expression for Pediatric Osteosarcoma

Search GEO for disease gene expression data for Pediatric Osteosarcoma.

Pathways for Pediatric Osteosarcoma

Pathways related to Pediatric Osteosarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.04 DHFR MTHFR SLC19A1
2
Show member pathways
11.66 DHFR MTHFR SLC19A1
3
Show member pathways
11.28 ATIC DHFR MTHFR
4 10.42 ATIC DHFR MTHFR SLC19A1

GO Terms for Pediatric Osteosarcoma

Biological processes related to Pediatric Osteosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metabolic process GO:0008152 9.54 ATIC HK2 MTHFR
2 one-carbon metabolic process GO:0006730 9.32 DHFR MTHFR
3 tetrahydrofolate metabolic process GO:0046653 9.26 DHFR MTHFR
4 tetrahydrofolate biosynthetic process GO:0046654 9.16 ATIC DHFR
5 dihydrofolate metabolic process GO:0046452 8.96 ATIC DHFR
6 folic acid metabolic process GO:0046655 8.8 DHFR MTHFR SLC19A1

Molecular functions related to Pediatric Osteosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 catalytic activity GO:0003824 9.33 ATIC HK2 MTHFR
2 NADP binding GO:0050661 8.96 DHFR MTHFR
3 folic acid binding GO:0005542 8.62 DHFR SLC19A1

Sources for Pediatric Osteosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....